Burosumab treatment for children younger than 12 months with X-linked hypophosphataemia [0.03%]
布舒苏玛治疗12个月以下X连锁低磷性佝偻病儿童
Salvatore Minisola,Jessica Pepe,Cristiana Cipriani
Salvatore Minisola
Charles Agyemang,John Tetteh,Maïmouna Ndour Mbaye et al.
Charles Agyemang et al.
The prevalence of type 2 diabetes is rising rapidly across sub-Saharan Africa; however, its epidemiology, clinical phenotypes, and underlying mechanisms remain insufficiently characterised. This first paper in a Series on diabetes in sub-Sa...
Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised study [0.03%]
布罗舒马努单抗治疗X连锁低磷血症婴儿的安全性、耐受性和药代动力学及有效性：一项开放标签、多中心、非随机研究
Agnès Linglart,Francesco Emma,Justine Bacchetta et al.
Agnès Linglart et al.
Background: Burosumab, a human anti-fibroblast growth factor 23 monoclonal antibody, is approved in Europe for treating X-linked hypophosphataemia (XLH) in patients aged at least 1 year. Early initiation might further imp...
Strengthening diabetes care in sub-Saharan Africa: health systems, digital innovations, lifestyle interventions, and socioeconomic dimensions [0.03%]
撒哈拉以南非洲糖尿病诊疗的强化：卫生系统、数字创新、生活方式干预及经济社会因素
Shabana Cassambai,Pamela Godia,Silver Bahendeka et al.
Shabana Cassambai et al.
The prevalence of diabetes, particularly type 2, in sub-Saharan Africa is rising at an alarming rate. This surge has exposed deep structural challenges, including an over-reliance on hospital-based services and strong cultural and faith-bas...
Diabetes in sub-Saharan Africa: aligning biology, culture, and health systems for improved outcomes [0.03%]
撒哈拉以南非洲的糖尿病：协调生物学、文化和卫生系统以改善结局
Louise M Goff,Anxious J Niwaha
Louise M Goff
Charlotte K Boughton
Charlotte K Boughton
Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial [0.03%]
连续葡萄糖监测与自我监测血糖在2型糖尿病患者中的对照研究：一项多中心随机开放标记优效性试验
Emma G Wilmot,Patrick Moore,Thozhukat Sathyapalan et al.
Emma G Wilmot et al.
Background: Type 2 diabetes is the most common metabolic disorder worldwide, accounting for about 90% of people living with diabetes. Glycated haemoglobin (HbA1c), a measure of chronic glycaemic exposure, correlates with ...
A conceptual framework for modernising and right-sizing global diabetes care [0.03%]
糖尿病护理现代化和优化的理论框架
Mohammed K Ali,Rodrigo M Carillo-Larco,Troels Krarup Hansen et al.
Mohammed K Ali et al.
Yu Mi Kang,Vanita R Aroda
Yu Mi Kang
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial [0.03%]
在日本和台湾超重或肥胖伴或不伴有2型糖尿病的成人中，卡利汀联合索马鲁肽与单独使用索马鲁肽疗效及安全性的比较：一项多中心、随机、积极对照的IIIa期试验（重新定义5）
Toshimasa Yamauchi,Niels-Peter Becker,Christoffer Andersen Hagemann et al.
Toshimasa Yamauchi et al.
Background: The combination of cagrilintide and semaglutide has been shown in global studies to induce reductions in bodyweight. We assessed the efficacy and safety of a fixed-dose combination of cagrilintide 2·4 mg and ...